QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 astria-therapeutics-alpha-star-phase-1b2-study-evaluating-navenibart-monoclonal-antibody-inhibitor-in-hereditary-angioedema-participants-shows-robust-attack-rate-reduction-favorable-safety-tolerability-profile

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

 astria-therapeutics-to-present-final-results-from-alpha-star-phase-1b2-trial-of-navenibart-in-people-living-with-hae-at-acaai-annual-scientific-meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

 hc-wainwright--co-downgrades-astria-therapeutics-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Neutral.

 wedbush-downgrades-astria-therapeutics-to-neutral-lowers-price-target-to-13

Wedbush analyst Laura Chico downgrades Astria Therapeutics (NASDAQ:ATXS) from Outperform to Neutral and lowers the price tar...

 jmp-securities-downgrades-astria-therapeutics-to-market-perform

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics (NASDAQ:ATXS) from Market Outperform to Market Perform.

 jefferies-downgrades-astria-therapeutics-to-hold-lowers-price-target-to-13

Jefferies analyst Eun Yang downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Hold and lowers the price target from $3...

 biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

 astria-therapeutics-to-present-new-data-on-its-drug-candidate-navenibart-at-2025-haei-regional-conference-emea-in-rome-italy

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

 astria-therapeutics-begins-opening-clinical-trial-sites-in-eu-and-may-begin-screening-participants-for-phase-3-alpha-orbit-trial-of-navenibart-for-hae-treatment

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

 hc-wainwright--co-maintains-buy-on-astria-therapeutics-raises-price-target-to-20

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and raises the price...

 cantor-fitzgerald-reiterates-overweight-on-astria-therapeutics-maintains-49-price-target

Cantor Fitzgerald analyst Steven Seedhouse reiterates Astria Therapeutics (NASDAQ:ATXS) with a Overweight and maintains $49 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION